Ryan Mee, CEO of Fulcrum Metals, reviews FY23 and progress on the Gold Tailings Hub in Canada. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,156.00
Bid: 12,124.00
Ask: 12,128.00
Change: -14.00 (-0.12%)
Spread: 4.00 (0.033%)
Open: 12,114.00
High: 12,258.00
Low: 12,114.00
Prev. Close: 12,170.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Single shot of Covid jab effective at preventing hospital admission

Mon, 01st Mar 2021 19:01

(Alliance News) - A single shot of the Pfizer Inc or Oxford-AstraZeneca PLC vaccine offers dramatic protection against hospital admission and severe disease in older people, according to a new study from Public Health England.

Health Secretary Matt Hancock hailed the "exciting" real-world data which found either vaccine is more than 80% effective at preventing hospital admission around three to four weeks after the first dose.

England's deputy chief medical officer Jonathan Van-Tam said the data offered a glimpse of how the vaccine programme "is going to hopefully take us into a very different world in the next few months".

The study, which has yet to be peer-reviewed, included more than 7.5 million people aged 70 and over in England.

The data also shows that infections, where people display symptoms, in the over-70s fall from around three weeks after one dose of both vaccines.

Protection against even developing symptomatic Covid-19 in the first place ranged between 57 and 61% for one dose of Pfizer and between 60% and 73% for the Oxford-AstraZeneca vaccine, the study found.

On top of the protection against symptomatic disease, people who had been vaccinated with one dose of Pfizer had an additional 43% lower risk of emergency hospital admission and an additional 51% lower risk of death, according to the study.

Meanwhile, people who had been vaccinated with one dose of the Oxford vaccine had an additional 37% lower risk of emergency hospital admission, while there is currently insufficient follow-up data to assess the impact on death.

The authors said that "both vaccines show similar effects", adding: "Combined with the effect against symptomatic disease, this indicates that a single dose of either vaccine is approximately 80% effective at preventing hospitalisation and a single dose of (Pfizer) is 85% effective at preventing death with Covid-19."

Hancock told a Downing Street press conference the study was "extremely good news".

He added: "In fact, the detailed data show that the protection that you get from catching Covid 35 days after a first jab is even slightly better for the Oxford jab than for Pfizer, albeit both results are clearly very strong."

The results "may also help to explain why the number of Covid admissions to intensive care units among people over 80 in the UK have dropped to single figures in the last couple of weeks".

Van-Tam told the briefing the data "gives us those first glimpses of how, if we are patient, and we give this vaccine programme time to have its full effect, it is going to hopefully take us into a very different world in the next few months".

Urging people to have their second doses, he added: "I think there's quite a significant likelihood that a second dose of vaccine is going to mature your immune response, possibly make it broader and almost certainly make it longer than it would otherwise be in relation to a first dose only."

That meant it was "absolutely critical" that second doses "are still part of the course of immunisation against Covid-19 and no less important for that reason".

Van-Tam said the latest scientific data had "vindicated" the UK's decision to give the AstraZeneca vaccine to older people.

Some countries have refused to administer the vaccine to the over-65s because of a lack of clinical trial data on older age groups.

However, Van-Tam said the Joint Committee on Vaccination & Immunisation had taken the view that it was "not immunologically plausible" the vaccine would work in younger age groups but not older ones.

He added: "We took a view that it almost certainly would work. The PHE data have clearly vindicated that approach today.

"I am not here to criticise other countries but to say that I think in time the data emerging from our programme will speak for itself and other countries will doubtless be very interested in it."

Mary Ramsay, PHE head of immunisation, said of the study: "This adds to growing evidence showing that the vaccines are working to reduce infections and save lives.

"While there remains much more data to follow, this is encouraging and we are increasingly confident that vaccines are making a real difference.

"It is important to remember that protection is not complete and we don't yet know how much these vaccines will reduce the risk of you passing Covid-19 on to others.

"Even if you have been vaccinated, it is really important that you continue to act like you have the virus, practise good hand hygiene and stay at home."

By Jane Kirby, PA Health Editor

source: PA

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
2 Jan 2024 08:26

AstraZeneca and Sanofi received approval in China for RSV antibody

(Alliance News) - AstraZeneca PLC and Sanofi SA's long-acting monoclonal antibody Beyfortus received approval for use in China to prevent respiratory syncytial virus disease, Astra said on Tuesday.

Read more
2 Jan 2024 07:57

LONDON BRIEFING: AstraZeneca, Sanofi's RSV treatment approved in China

(Alliance News) - Stock prices in London are expected to open higher on Tuesday, reacting to a slight expansion in manufacturing activity in China and ahead of a slew of manufacturing PMI data including for the UK.

Read more
27 Dec 2023 17:04

Rate-cut optimism, autos push UK stocks higher

FTSE 100 up 0.4%, FTSE 250 adds 0.5%

*

Read more
27 Dec 2023 17:02

LONDON MARKET CLOSE: Stocks start week higher as 2024 draws to close

(Alliance News) - Equities in London kicked off an abbreviated trading week with gains on Wednesday, on continued US interest rate optimism at the end of 2024.

Read more
27 Dec 2023 14:25

London close: Stocks maintain gains amid post-Christmas rally

(Sharecast News) - London's stock markets closed in positive territory on Wednesday, buoyed by a global surge in stock prices as the S&P 500 neared an all-time high on Wall Street.

Read more
27 Dec 2023 12:06

LONDON MARKET MIDDAY: Stocks hold onto gains amid US rate cut hopes

(Alliance News) - London's FTSE 100 index was outperforming other European stock-price measures at midday on Wednesday, boosted by gains for miners and industrials.

Read more
27 Dec 2023 11:20

London midday: Stocks ride global wave of post-Christmas optimism

(Sharecast News) - London's equity markets were still above the waterline at lunchtime on Wednesday, following a late Santa rally on Wall Street overnight.

Read more
27 Dec 2023 08:48

LONDON MARKET OPEN: FTSE 100 gains led by miners and industrials

(Alliance News) - Stock prices in London opened in the green on Wednesday, as hopes for US interest rate cuts in the new year continued to propel global equities higher.

Read more
27 Dec 2023 08:26

London open: FTSE takes cues from Wall Street 'Santa rally'

(Sharecast News) - London's stocks returned from the Christmas break in the green on Wednesday, boosted by a late Santa rally on Wall Street overnight.

Read more
27 Dec 2023 08:24

TOP NEWS: AstraZeneca buys Gracell to "enrich" cell therapy pipeline

(Alliance News) - AstraZeneca PLC on Tuesday said it has agreed to acquire Gracell Biotechnologies Inc, paying about USD1.2 billion for the clinical-stage company.

Read more
27 Dec 2023 07:52

LONDON BRIEFING: AstraZeneca buys Gracell Biotech; COPL CEO resigns

(Alliance News) - Stocks in London were expected to make gains at Wednesday's market open, as investors continued to pin their hopes on US interest rate cuts.

Read more
27 Dec 2023 07:02

AstraZeneca to buy Gracell Technologies for $1.2bn

(Sharecast News) - AstraZeneca on Wednesday said it was buying Gracell Biotechnologies, a global clinical-stage biopharmaceutical company developing cell therapies for the treatment of cancer and autoimmune diseases, for $1.2bn.

Read more
26 Dec 2023 21:26

Wall Street ends higher in final stretch of 2023, rate cuts in view

Intel up on $3.2 bln grant from Israel

*

Read more
26 Dec 2023 21:00

Wall Street ends higher in final stretch of 2023, rate cuts in view

Intel up on $3.2 bln grant from Israel

*

Read more
26 Dec 2023 19:41

Wall Street gains on final stretch of 2023, rate cuts in view

Intel up on $3.2 bln grant from Israel

*

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.